Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics.
about
Targeting the intragraft microenvironment and the development of chronic allograft rejectionTubulointerstitial injury and the progression of chronic kidney diseaseNegative health implications of sickle cell trait in high income countries: from the football field to the laboratoryNew magnetic resonance imaging methods in nephrologyRenal tubular HIF-2α expression requires VHL inactivation and causes fibrosis and cystsFluorescent microangiography is a novel and widely applicable technique for delineating the renal microvasculatureHIF- and non-HIF-regulated hypoxic responses require the estrogen-related receptor in Drosophila melanogasterChronic renal ischemia in humans: can cell therapy repair the kidney in occlusive renovascular disease?A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the ratScience to practice: Renal hypoxia and fat deposition in diabetic neuropathy--new insights with functional renal MR imagingInhibition of the purinergic P2X7 receptor improves renal perfusion in angiotensin-II-infused rats.Human nephrosclerosis triggers a hypoxia-related glomerulopathySilencing of hypoxia-inducible factor-1α gene attenuates chronic ischemic renal injury in two-kidney, one-clip rats.Modeling Glucose Metabolism in the Kidney.Advances in understanding ischemic acute kidney injury.Acute kidney injury: a springboard for progression in chronic kidney diseaseSignalling pathways involved in hypoxia-induced renal fibrosis.Human adipose stromal cell therapy improves survival and reduces renal inflammation and capillary rarefaction in acute kidney injury.Nocturnal hypoxia and loss of kidney function.Lipocalin 2 is essential for chronic kidney disease progression in mice and humans.Dynamic multiphoton microscopy: focusing light on acute kidney injury.Hypoxia and oxidative stress markers in pediatric patients undergoing hemodialysis: cross section studyEffects of iodinated contrast agents on renal oxygenation level determined by blood oxygenation level dependent magnetic resonance imaging in rabbit models of type 1 and type 2 diabetic nephropathy.Oxygen regulation of the epithelial Na channel in the collecting ductMethods to study the tumor microenvironment under controlled oxygen conditions.A2B adenosine receptor-mediated induction of IL-6 promotes CKD.Hypoxia-inducible factor-1α contributes to the profibrotic action of angiotensin II in renal medullary interstitial cellsInteraction of peroxiredoxin V with dihydrolipoamide branched chain transacylase E2 (DBT) in mouse kidney under hypoxia.Renal oxygenation in acute renal ischemia-reperfusion injury.Determinants of renal tissue oxygenation as measured with BOLD-MRI in chronic kidney disease and hypertension in humansFibrosis and progression of autosomal dominant polycystic kidney disease (ADPKD).Silencing of hypoxia-inducible factor-1α gene attenuated angiotensin II-induced renal injury in Sprague-Dawley rats.Functional interaction between angiotensin II receptor type 1 and chemokine (C-C motif) receptor 2 with implications for chronic kidney diseaseLung transplant airway hypoxia: a diathesis to fibrosis?Multi-Parametric Evaluation of Chronic Kidney Disease by MRI: A Preliminary Cross-Sectional Study.Cells of renin lineage express hypoxia inducible factor 2α following experimental ureteral obstruction.Cellular and molecular mechanisms of renal fibrosis.Effect of Proteinuria and Glomerular Filtration Rate on Renal Outcome in Patients with Biopsy-Proven Benign NephrosclerosisThe unfolded protein response regulates an angiogenic response by the kidney epithelium during ischemic stressContinuous AMD3100 Treatment Worsens Renal Fibrosis through Regulation of Bone Marrow Derived Pro-Angiogenic Cells Homing and T-Cell-Related Inflammation.
P2860
Q26852762-ADE7EBB5-FA16-4EF5-901E-EBC1A1CC1231Q26852862-C43B12EE-071B-4BCC-8323-97C8DF8CBF45Q26862794-D361A674-9395-4683-84B4-471E5994282CQ26866166-B207E35A-57CF-4D22-93A5-8287DA17964AQ27309141-64C0C9FA-4E76-4100-ACBE-66400E8AFCA7Q27320632-07B6D7E7-80C7-43DA-962D-77893B262BF4Q27324988-58F38606-8928-457C-BB39-ECC4417F3F49Q28085141-26F428B6-5C68-4809-9C76-E8E33F70F950Q28484321-ACCDD93C-E1D1-4263-B14D-7D2092A411F5Q28828595-513599E3-240C-4C75-9DC7-1F9A8623F887Q30384751-F085BFE1-381C-4AEF-A902-EE12F40C1743Q33597077-0E84EF40-03AD-449A-A411-39140D11340AQ33626606-A463F52C-E419-4BC3-8D76-05096ECA62E6Q33683963-46EC7BAA-FF8D-4F0F-8842-8EC59D0D29DBQ33810644-B70C73A6-CC72-4A1A-A0EC-08DD0887ED91Q33840576-1A1DED37-B170-4BC6-996C-CAD1856D547BQ33844658-F91131B7-730B-4D78-9281-52E93D344DF3Q33844666-BFEB80AA-6B1E-4E9F-84B6-8A9AC01AD449Q33895268-26F15C78-50A1-415D-ABEB-63F05B019610Q34245315-972408A6-8D4C-43D8-B1AD-4AB10ACD7117Q34428919-722BA414-BE48-4184-AE89-96C7F2636BBAQ34444354-F4553542-3F31-42FE-B535-937D0374E3CFQ34538665-BF6AF8B0-8311-44BE-8397-9865BBD6B1DAQ34599900-2CB2B8D8-F552-40C2-A782-CE9F5BC81545Q34622961-0CD88CC4-DF70-4D58-AC05-74FF53017048Q34870775-69EF3D59-F1FC-4248-ACB1-CA7E5C8E5E75Q35022857-D99AF578-B934-4E83-BD74-C1B805B5C583Q35068160-CE1A87E4-29CF-4826-A44E-FC2031C413CFQ35112037-CDF8A4AD-AAA2-4CE1-9355-4F96B516294DQ35156220-C5076B9F-C273-4E4B-BF4C-DD15934CDF17Q35194509-D8AC0745-C2FC-4F55-90AF-91461AD2EBE4Q35216335-73B67451-66A6-4318-A204-8A2C5664FA21Q35217148-DE8DF0EE-1AA3-4DF7-9DFE-48965F737F61Q35716146-3B89F6A3-2E0F-4F86-8814-9CA335BDEBEBQ35796544-0E8EFC69-0AC0-4CCA-A58A-287CD4EDA72FQ35889114-19E13EBD-95FF-4EF7-A3A8-4A351F40C86CQ35903772-41B880AD-CB74-4B87-A56D-C80186DDD2E8Q35904061-03AFE117-35E9-4786-BD2D-E313868B8FB2Q35922593-78D183E6-FBCA-4A56-81F9-B31908626527Q35930523-58F05F6A-3F48-4E4F-8704-1920659216E5
P2860
Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chronic hypoxia as a mechanism ...... othesis to novel therapeutics.
@en
Chronic hypoxia as a mechanism ...... othesis to novel therapeutics.
@nl
type
label
Chronic hypoxia as a mechanism ...... othesis to novel therapeutics.
@en
Chronic hypoxia as a mechanism ...... othesis to novel therapeutics.
@nl
prefLabel
Chronic hypoxia as a mechanism ...... othesis to novel therapeutics.
@en
Chronic hypoxia as a mechanism ...... othesis to novel therapeutics.
@nl
P356
P1433
P1476
Chronic hypoxia as a mechanism ...... othesis to novel therapeutics.
@en
P2093
Jill T Norman
Leon G Fine
P2888
P304
P356
10.1038/KI.2008.350
P407
P577
2008-07-16T00:00:00Z